Innovative method to treat Alzheimer's in mice

Innovative method to treat Alzheimer's in mice
Amyloid-beta peptide in the brain of the mouse model, before gene transfer using AAV.

Researchers from the RIKEN Brain Science Institute report that they successfully used a virus vector to restore the expression of a brain protein and improve cognitive functions, in a mouse model of Alzheimer's disease.

The researchers, led by Dr Takaomi Saido, developed an adeno-associated virus (AAV) vector carrying the neprilysin gene that they administered to neprilysin-deficient mice. Because it is impossible to deliver genes directly to the brain without surgery, the researchers injected the virus in the of the heart, as this provides a direct route to the brain.

Innovative method to treat Alzheimer's in mice
Amyloid-beta peptide in the mouse model after the gene transfer.

They show that neprilysin was expressed in the brain of the mice and that this resulted in a decrease in the accumulation of amyloid-beta peptide, the protein responsible for cognitive decline in Alzheimer's patients. The researchers also observe a reduction of the symptoms associated with Alzheimer's disease in the mice, such as memory loss. These results point towards a new therapeutic strategy for Alzheimer's disease and other neurodegenerative diseases.

More information: The results are presented in the journal Scientific Reports, DOI: 10.1038/srep01472

add to favorites email to friend print save as pdf

Related Stories

Characterizing a toxic offender

Dec 09, 2011

The brains of individuals with Alzheimer's disease contain protein aggregates called plaques and tangles, which interfere with normal communication between nerve cells and cause progressive learning and memory ...

The good and the bad of a potential Alzheimer's target

Jun 27, 2008

Research in fruit flies has shown that enhancing the production of a protein called neprilysin can reduce the formation of plaques and neuron death associated with Alzheimer's, at the expense of reducing the flies' lifespan.

Recommended for you

Putting dementia carers in control

5 hours ago

Experts will explore how improved support and powers for people caring for loved-ones with dementia can improve quality of life for both patients and carers around the UK.

Lilly, AstraZeneca team up on Alzheimer's drug

Sep 16, 2014

Eli Lilly and Co. plans to pay up to $500 million to fellow drugmaker AstraZeneca as part of a collaboration to develop and sell a potential Alzheimer's disease treatment that is in the early stages of clinical testing.

Report finds scale and cost of dementia escalates

Sep 11, 2014

Dementia UK: The Second Edition, prepared by King's College London and the London School of Economics for the Alzheimer's Society, finds that the cost of dementia to the UK has hit £26 billion a year and ...

User comments